Opportunity for pharmacogenomic testing in patients with cystic fibrosis.

Colleen M SakonLeah A AliceaHeather PataccaCynthia D BrownTodd C SkaarEmma M Tillman

Published in: Pediatric pulmonology (2022)

Patients with CF have high utilization of drugs with CPIC guidelines, therefore preemptive pharmacogenomic testing should be considered in CF patients at the time of CFTR genetic testing.

Keyphrases

cystic fibrosis
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes